Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Rolf Pokorny"'
Autor:
Luis Lopez-Lazaro, Stephan Duparc, Jangsik Shin, Rolf Pokorny, Robert M Miller, Lawrence Fleckenstein, Isabelle Borghini-Fuhrer, Carrie A. Morris, Sarah Arbe-Barnes
Publikováno v:
Antimicrobial Agents and Chemotherapy
The objectives of this study were to characterize any drug-drug interaction between the antimalarial Pyramax (pyronaridine-artesunate [PA]) and the CYP2D6 probe substrate metoprolol and to assess the safety of 60-day or 90-day PA redosing, particular
Autor:
Peter N. Lohstroh, Donald Jung, Luis Lopez-Lazaro, Stephen R. Dueker, Lawrence Fleckenstein, Xin-Ping Fang, Mark Baker, Jangsik Shin, Carrie A. Morris, Li-Quan Wang, Rolf Pokorny, Stephan Duparc, Isabelle Borghini-Fuhrer
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 40:75-86
This was a single dose mass balance and metabolite characterization study of the antimalarial agent pyronaridine. Six healthy male adults were administered a single oral dose of 720 mg pyronaridine tetraphosphate with 800 nCi of radiolabeled (14)C-py
Autor:
Rolf Pokorny, Thomas Blättler, Manfred Hösle, Zhen Zhu, Diana Frey, Stephen G. Carter, Alfons Loher, Gyula Varadi
Publikováno v:
Pain Physician. :E749-E762
Background: Osteoarthritis is a common condition, typically treated with orally administered analgesics and non-steroidal anti-inflammatory drugs (NSAIDs). Chronic administration of NSAIDs, serotoninnorepinephrine reuptake inhibitors (SNRIs, i.e., du
Autor:
Janthima Methaneethorn, Luis Lopez-Lazaro, Lawrence Fleckenstein, Isabelle Borghini-Fuhrer, Carrie A. Morris, Stephan Duparc, Chang-Sik Shin, Rolf Pokorny, Donald Jung
Publikováno v:
The American Journal of Tropical Medicine and Hygiene
A multiple dose, parallel group study was conducted to assess for a drug-drug interaction between the pyronaridine/artesunate (PA) combination antimalarial and ritonavir. Thirty-four healthy adults were randomized (1:1) to receive PA for 3 days or PA
Autor:
Paul Chaplin, Amanda Handley, Petra Rapp, Lyn Mateo, Niels Wulff, Herwig Kollaritsch, Alfred von Krempelhuber, Rolf Pokorny, Jens Vollmar, Henriette Siersbol, Barbara Petzold
Publikováno v:
Vaccine. 28:1209-1216
IMVAMUNE is a Modified Vaccinia Ankara (MVA)-based virus that is being developed as a safer 3rd generation smallpox vaccine. In order to determine the optimal dose for further development, a double-blind, randomized Phase II trial was performed testi
Publikováno v:
Current Medical Research and Opinion. 22:501-509
Establishing local tolerability of transdermal opioid systems is important as more systems become available for use in a range of indications. We compared the skin irritation potential of a single application of transdermal fentanyl (Durogesic D-tran
Autor:
Monique Ben-Am, Felix Waldmeier, Hans-Peter Gschwind, Rolf Pokorny, Michael Hayes, Ulrike Pfaar, Bin Peng, Peter Zbinden, Markus Zollinger, Gerhard Gross, Michael Seiberling, Claudia Sayer
Publikováno v:
Drug Metabolism and Disposition. 33:1503-1512
Imatinib mesylate (GLEEVEC, GLIVEC, formerly STI571) has demonstrated unprecedented efficacy as first-line therapy for treatment for all phases of chronic myelogenous leukemia and metastatic and unresectable malignant gastrointestinal stromal tumors.
Autor:
Frank Weber, Rolf Pokorny, Antje Meyer, Ronald Black, Inge Lues, Konrad Glund, Hans-Ulrich Demuth, Torsten Hoffman
Publikováno v:
Alzheimer's & Dementia. 9
Autor:
Rolf Pokorny, Hans-Dietrich Heilmann, Harald Labischinski, Arne Andresen, Heena Patel, Will Stubbings, Michael Seiberling, Luis Lopez-Lazaro, Andreas Vente
Finafloxacin is a new fluoroquinolone antibiotic with the unique property of increasing antibacterial activity at pH values lower than neutral. Whereas its antibacterial activity at neutral pH matches that of other quinolones in clinical use, it is e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::127826b67048d699900ccb1c23dc3dad
https://europepmc.org/articles/PMC3165282/
https://europepmc.org/articles/PMC3165282/
Autor:
Alois B. Lang, Peter Durrer, Rolf Pokorny, Adrian W. Zuercher, Martin A. Imboden, Hedvika Lazar, Michael P. Horn, Christophe Hammer, Michael Seiberling
Publikováno v:
Antimicrobial agents and chemotherapy. 53(8)
KBPA-101 is a human monoclonal antibody of the immunoglobulin M isotype, which is directed against the O-polysaccharide moiety of Pseudomonas aeruginosa serotype O11. This double-blind, dose escalation study evaluated the safety and pharmacokinetics